This latter study estimated BDNF Met carriers with the APOE ε4 allele would have clinically significant cognitive impairment in 3 years, as compared to 10 years if the individual was an APOE ε4 carrier and BDNF Val homozygote. This evidence concerns the gene APOE and Cognitive impairment.